MRNA vs MSTR

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 06, 2026

MRNA

48.8
AI Score
VS
MRNA Wins

MSTR

48.7
AI Score

Investment Advisor Scores

MRNA

49score
Recommendation
HOLD

MSTR

49score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MRNA MSTR Winner
Revenue 534.00M 246.67M MRNA
Net Income -2.13B -20.76B MRNA
Net Margin -397.9% -8417.1% MRNA
Operating Income -2.20B -22.80B MRNA
ROE -31.4% -67.2% MRNA
ROA -19.4% -39.5% MRNA
Total Assets 10.96B 52.56B MSTR
Cash 1.72B 1.71B MRNA
Debt/Equity 0.09 0.22 MRNA
Current Ratio 2.29 5.39 MSTR
Free Cash Flow -1.25B 7.13M MSTR

Relative Price Performance (Last 90 Days)

MRNA 1M: -22.7% · 3M: +21.9% MSTR 1M: +6.5% · 3M: -44.4%

Current Technical Phase

MRNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 50.2 · Price: $59.17

MSTR

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 50

RSI (14): 50.4 · Price: $100.01

Fundamentals Snapshot

Metric MRNA MSTR
Market Cap
Forward P/E -11.0 19.2
Trailing P/E
Revenue (TTM)
Revenue Growth 0.0% 0.1%
Gross Margin -0.7% 0.7%
Operating Margin -5.6% -68.1%
EPS -7.88 -97.62
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate, winning 8 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.